Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Buprenorphine has been proven effective in treating opioid use disorder. However, the high cost of buprenorphine and the limited prescribing capacity may restrict access to this effective medication-assisted treatment for opioid use disorder. Objective: To examine whether Medicaid expansion and physician prescribing capacity may have impacted buprenorphine utilization covered by Medicaid. Research Design: We used a quasi experimental difference-in-differences design to compare the pre-post changes in Medicaid-covered buprenorphine prescriptions and buprenorphine spending between the 26 states that implemented Medicaid expansions under the Affordable Care Act in 2014 and those that did not. Subjects: All Medicaid enrollees in the expansion states and the nonexpansion and late-expansion states. Measures: Quarterly Medicaid prescriptions for buprenorphine and spending on buprenorphine from the Centers for Medicare and Medicaid Services Medicaid Drug Utilization files 2011 to 2014. Results: State implementation of Medicaid expansions in 2014 was associated with a 70% increase (P<0.05) in Medicaid-covered buprenorphine prescriptions and a 50% increase (P<0.05) in buprenorphine spending. Physician prescribing capacity was also associated with increased buprenorphine utilization. Conclusions: Medicaid expansion has the potential to reduce the financial barriers to buprenorphine utilization and improve access to medication-assisted treatment of opioid use disorder. Active physician participation in the provision of buprenorphine is needed for ensuring that Medicaid expansion achieves its full potential in improving treatment access.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How Much Should We Trust Differences-in-Differences Estimates?
Bertrand, M., Duflo, E., & Mullainathan, S. (2004) · The Quarterly Journal of Economics · doi:10.1162/003355304772839588 · Cited by 10,641
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 1×
“Compared with other FDA-approved medications such as methadone and naltrexone, buprenorphine has relatively high patient retention and sustained recovery as well as low addition liability and minimum overdose risk.(8,9) Furthermore, buprenorphine is the only type of medication-assisted treatment of opioid use disorder…”
BackgroundCounseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Cited by
Kelly, J. F., Bergman, B. G., Hoeppner, B. B., Vilsaint, C., & White, W. L. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.09.028 · Cited by 339
Maclean, J. C., & Saloner, B. (2019) · Journal of Policy Analysis and Management · doi:10.1002/pam.22112 · Cited by 153
Access to Health Care and Criminal Behavior: Short-Run Evidence from the ACA Medicaid Expansions
Vogler, J. (2017) · SSRN Electronic Journal · doi:10.2139/ssrn.3042267 · Cited by 18
Han, B., Compton, W. M., Jones, C. M., Stimson, D. T., Barfield, E. T., Bellgowan, J. F., Hobin, J. A., & Volkow, N. D. (2026) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.26m16340
Metadata
- Authors
- Wen, H., Hockenberry, J. M., Borders, T. F., & Druss, B. G.
- Venue
- Medical Care
- Published
- 2017-04
- Volume
- 55
- Issue
- 4
- Pages
- 336-341
- ISSN
- 0025-7079 (ISSN-L)
- OpenAlex
- W2606583128
- Cited by
- 165
- References
- 5
- FWCI
- 17.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment. https://app.cochat.ai/papers/10.1097/mlr.0000000000000703
- The paper
- Wen, H., Hockenberry, J. M., Borders, T. F., & Druss, B. G. (2017). Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment. Medical Care. https://doi.org/10.1097/mlr.0000000000000703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.